CAR T-cell Therapy Landscape

CE / CME

Understanding and Communicating Current Evidence for CAR T-Cell Therapy

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurse Practitioners: 0.50 Nursing contact hours, includes 0.50 hour of pharmacotherapy credit

Released: September 26, 2024

Expiration: September 25, 2025

Lisa Nodzon
Lisa Nodzon, PhD, APRN, AOCNP

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

What is a key difference between CAR T-cell therapy and bispecific antibody therapy?

2.

Your 59-yr-old fit patient with R/R CLL with del(17p) progressed on first-line acalabrutinib and is now progressing on second-line venetoclax + rituximab. Which therapy would you recommend next?